Clinical Trials Browser

Completed × surufatinib × Gastrointestinal × Clear all

NCT05481463 2025-05-28

Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT02966821 2019-02-27

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms